ENVIRONMENTAL DISCLOSURE PRACTICES IN THE INDIAN PHARMACEUTICAL INDUSTRY: A COMPARATIVE STUDY OF SUN PHARMACEUTICAL LTD. AND CIPLA LTD

The pharmaceutical industry, integral to global healthcare, faces increasing pressure to address its environmental
footprint through robust accounting and reporting practices. This study conducts a comparative analysis of the
environmental disclosure and reporting practices of two leading Indian pharmaceutical companies, Sun Pharma and
Cipla Ltd., utilizing secondary data sourced from their sustainability reports, annual disclosures, and industry
frameworks. The research evaluates the adoption of global standards such as the Global Reporting Initiative (GRI)
and the Carbon Disclosure Project (CDP), focusing on key environmental metrics including greenhouse gas
emissions, energy consumption, water management, and waste reduction. It examines the structure, transparency,
and frequency of their environmental disclosures, highlighting how each company integrates environmental
disclosure into its strategic framework. The findings reveal distinct approaches: Sun Pharma emphasizes detailed
quantitative metrics with a focus on renewable energy adoption, while Cipla prioritizes narrative-driven reports
highlighting community-focused environmental initiatives. The study identifies strengths, such as Sun Pharma’s data
granularity, and weaknesses, including Cipla’s limited disclosure of scope-specific emissions. By comparing their
practices, the paper uncovers gaps in standardization and transparency, offering insights into how these firms align
with global sustainability goals amidst India’s regulatory landscape. This analysis contributes to understanding the
role of environmental accounting in enhancing corporate accountability in the pharmaceutical sector, emphasizing
the need for consistent, accessible, and comprehensive reporting to address stakeholder expectations and
environmental challenges effectively.